DEF: Merit Medical Systems Sets Date for 2025 Annual Shareholder Meeting, Highlights Strong 2024 Performance

Merit Medical Systems announces its 2025 Annual Meeting of Shareholders to be held virtually on May 14, 2025, following a year of strong financial results and strategic advancements.

Summary

• Merit Medical Systems will hold its 2025 Annual Meeting of Shareholders virtually on May 14, 2025.
• The meeting will cover the election of four directors, an advisory vote on executive compensation, and the ratification of the appointment of Deloitte & Touche LLP as the independent registered public accounting firm.
• In 2024, Merit Medical achieved record revenue of $1.357 billion and strong free cash flow generation of over $185 million.
• The company successfully completed the first year of its Continued Growth Initiatives Program (CGI Program).
• Key acquisitions during the year included the EsophyX Z+ device from EndoGastric Solutions and the lead management portfolio from Cook Medical.
• The FDA also approved the WRAPSODY Cell-Impermeable Endoprosthesis, expanding Merit's renal therapies business.
• The Board recommends voting FOR all director nominees, the advisory vote on executive compensation, and the ratification of Deloitte's appointment.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results, strategic acquisitions, and FDA approvals. The company is on track to meet its goals, and shareholder support is high.

Positives

• Strong financial performance in 2024, including record revenue and free cash flow.
• Successful completion of the first year of the CGI Program.
• Strategic acquisitions to strengthen the company's market position.
• FDA approval of new products, expanding the company's offerings.
• High shareholder support for the executive compensation program.
• Commitment to sustainability and reducing environmental footprint.

Risks

• Most of Merit's products are disposable medical devices and are generally discarded after a single use due to the risks of exposing patients to bloodborne pathogens capable of transmitting disease or other potentially infectious materials.
• Climate risks and opportunities impact Merit's long-term resiliency as a global medical device leader.

Future Outlook

The company is on track to achieve the three-year targets of its CGI Program relating to revenue, operating margin, and free cash flow generation.

Management Comments

• We finished 2024 with strong momentum by delivering better-than-expected financial results in the fourth quarter, reflecting continued strong execution.
• We successfully completed the first year of our Continued Growth Initiatives Program ( CGI Program ).
• As a result, we continue to strengthen profitability, deliver top-line growth, and drive continuous innovation in the marketplace.
• We saw record-setting revenue and achieved operating margin and free cash flow levels that yielded shareholder returns at the upper end of our peer group.

Industry Context

The acquisitions of the EsophyX Z+ device and the lead management portfolio from Cook Medical strengthen Merit Medical's position in the gastrointestinal and electrophysiology/cardiac rhythm management markets, respectively.

Comparison to Industry Standards

• Merit Medical's executive compensation peer group includes companies such as CONMED Corporation, Globus Medical, Inc., Haemonetics Corporation, ICU Medical, Inc., Inari Medical, Inc., Insulet Corporation, Integer Holdings Corporation, Integra LifeSciences Holdings Corporation, LivaNova Plc, Masimo Corporation, Nevro Corp, Orthofix Medical, Inc., Penumbra, Inc., QuidelOrtho Corporation, and Teleflex Incorporated.
• The median revenue of this peer group is $1.611 billion, and the median market capitalization is $3.804 billion.
• Merit Medical's revenue of $1.357 billion and market capitalization of $5.682 billion place it within the range of its peers.

Management Changes

Corporate Governance

Related Party Transactions

• In 2024, the Company provided to Joseph C. Wright, the former President of the Company, total cash and equity compensation of $3,724,475.
• For the year ended December 31, 2024, the Company sold products totaling approximately $3.9 million in revenue to hospitals within the SSM Health system, where Laura S. Kaiser serves as the President and Chief Executive Officer.

Stakeholder Impact

• Shareholders will have the opportunity to vote on key proposals at the Annual Meeting.
• Employees may receive bonus payments based on the company's achievement of operating margin targets.
• The company's sustainability efforts aim to reduce its environmental footprint and benefit communities.
• The company's compliance and anti-corruption policies are designed to ensure interactions with healthcare professionals and healthcare organizations will benefit patients and enhance the practice of medicine.

Next Steps

• Shareholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will release its 2024 Sustainability Report in May 2025.
• The Board will continue to review shareholder voting results and consider changes to the executive compensation program.
• The Governance Committee will continue to seek opportunities to consult with major shareholders.

Key Dates

Keywords

Annual Meeting, Shareholders, Executive Compensation, Director Election, Financial Results, Acquisitions, FDA Approval, Sustainability, Merit Medical Systems